Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Helsinn Articles

Vifor gets certain rights to Helsinn's netupitant-palonosetron

16 May 2013

Helsinn grants anamorelin rights to Stendhal for Latin American countries

29 January 2013

Helsinn out-licenses netupitant-palonosetron fixed dose combo in South Korea

25 September 2012

Helsinn moving forward with supportive cancer care products anamorelin and netupitant + palonosetron

26 September 2011

Controversial NSAID nimesulide now banned in China for children below 12

23 May 2011

Helsinn and Taiho Pharma to extend relationship with CINV drug accord

14 April 2011

Helsinn Healthcare enters strategic alliance with IS Pharma, including selling Irish unit

2 February 2011

Zealand Pharma gets milestone from Helsinn on ZP1846 progress

10 December 2010

Helsinn licenses anti-nausea drug Aloxi to Specialised Therapeutics for Australian and New Zealand cancer patients

2 November 2010

Swiss firm Helsinn opens new $16.7 million R&D center in Ireland

7 September 2010

Helsinn's second-generation 5-HT3 RA Aloxi to expand in Asia via deal with Mundipharma

7 July 2010

Helsinn Healthcare and Eisai extend relationship, including US Aloxi marketing

10 June 2010

Showing 1-12 of 12 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Is the diabetes market facing a blockbuster-free future?
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS